Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney

28Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background and Purpose: Generation of cGMP via NO-sensitive soluble guanylyl cyclase (sGC) has been implicated in the regulation of renal functions. Chronic kidney disease (CKD) is associated with decreased NO bioavailability, increased oxidative stress and oxidation of sGC to its haem-free form, apo-sGC. Apo-sGC cannot be activated by NO, resulting in impaired cGMP signalling that is associated with chronic kidney disease progression. We hypothesised that sGC activators, which activate apo-sGC independently of NO, increase renal cGMP production under conditions of oxidative stress, thereby improving renal blood flow (RBF) and kidney function. Experimental Approach: Two novel sGC activators, runcaciguat and BAY-543, were tested on murine kidney. We measured cGMP levels in real time in kidney slices of cGMP sensor mice, vasodilation of pre-constricted glomerular arterioles and RBF in isolated perfused kidneys. Experiments were performed at baseline conditions, under L-NAME-induced NO deficiency, and in the presence of oxidative stress induced by ODQ. Key Results: Mouse glomeruli showed NO-induced cGMP increases. Under baseline conditions, sGC activator did not alter glomerular cGMP concentration or NO-induced cGMP generation. In the presence of ODQ, NO-induced glomerular cGMP signals were markedly reduced, whereas sGC activator induced strong cGMP increases. L-NAME and ODQ pretreated isolated glomerular arterioles were strongly dilated by sGC activator. sGC activator also increased cGMP and RBF in ODQ-perfused kidneys. Conclusion and Implication: sGC activators increase glomerular cGMP, dilate glomerular arterioles and improve RBF under disease-relevant oxidative stress conditions. Therefore, sGC activators represent a promising class of drugs for chronic kidney disease treatment. LINKED ARTICLES: This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc.

References Powered by Scopus

Fiji: An open-source platform for biological-image analysis

43315Citations
N/AReaders
Get full text

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

6656Citations
N/AReaders
Get full text

ImageJ2: ImageJ for the next generation of scientific image data

4285Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease

21Citations
N/AReaders
Get full text

Effect of Avenciguat on Albuminuria in Patients with CKD Two Randomized Placebo-Controlled Trials

14Citations
N/AReaders
Get full text

Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics

9Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Stehle, D., Xu, M. Z., Schomber, T., Hahn, M. G., Schweda, F., Feil, S., … Bénardeau, A. (2022). Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney. British Journal of Pharmacology, 179(11), 2476–2489. https://doi.org/10.1111/bph.15586

Readers' Seniority

Tooltip

Researcher 4

67%

PhD / Post grad / Masters / Doc 2

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

57%

Agricultural and Biological Sciences 2

29%

Biochemistry, Genetics and Molecular Bi... 1

14%

Save time finding and organizing research with Mendeley

Sign up for free